Amplification or over-expression of MYCN or MYCL1 is frequently observed in lung cancer (MYCN, MYCL1), ovarian cancer (MYCL1), breast cancer (MYCN), and cancers of neural origin including glioblastoma (MYCL1, MYCN), medulloblastoma (MYCN), and neuroblastoma (MYCN) [22]. This evidence concerns the gene MYCN and glioblastoma.